You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company also entered into two separate financing agreements totaling $41.5 million with Innovatus Life Sciences Lending Fund, East West Bank, and Aspire Capital.
The firm used about $38.8 million on Feb. 1 to repay all outstanding principal, interest, related fees, and other obligations under an existing loan agreement.
Karius said it will use the money to continue commercialization of its diagnostic technologies and to fund clinical studies, among other things.
The agreement amends and restates an existing loan and security agreement between NanoString and SVB to increase the size of the revolving loan facility to $20 million.
The company will use the proceeds in part to develop its Next Generation Profiling offering to analyze cancer genomes, transcriptomes, and proteomes with clinical outcome data.
The senior unsecured term loan facility was used, in part, to refinance a three-year loan agreement between BD, Citibank, and other lenders reached last year.
The company ended 2017 with $10 million in cash and cash equivalents, and raised $40 million in a public offering in January.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.
Perceptive Credit Holdings has agreed to provide the company with the loan, which CareDx said it will use to repay outstanding debt.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
In Nature this week: the largest known collection of human genetic variants, and more.